Genenta Science S.p.A. (NASDAQ:GNTA) said it is continuing to work with DC Advisory to assess potential collaboration opportunities for its biotechnology platform, which stems from research conducted by founder-scientists Professor Luigi Naldini and Bernhard Gentner. The company noted that DC Advisory has not identified any strategic partners to date and that Genenta is not currently engaged in discussions concerning either its Temferon therapy or its broader biotechnology platform.
The Milan-based firm is undergoing a strategic transformation into Saentra Forge, subject to shareholder approval. Under the new structure, the company aims to act as an industrial consolidator targeting sectors such as biotechnology, defense, aerospace and technologies tied to national security. Chief Executive Officer Pierluigi Paracchi said the strategy will focus on identifying promising scale-up companies in areas relevant to national security and supporting them with capital, operational structure and access to U.S. public markets through Genenta’s Nasdaq listing.
Paracchi also stated that he has retained all of his shares and has increased his stake by purchasing American Depositary Shares during permitted trading periods. He added that the company opposes any sale of shares by the founder-scientists unless Temferon obtains significant third-party validation.
The planned transformation marks a major shift from Genenta’s original focus on biotechnology development. The company said it will continue exploring partnership opportunities for its biotech platform based on the scientific research and early clinical data generated to date.
Genenta described its revised strategy as the creation of an industrial aggregation platform operating in strategically sensitive industries including cybersecurity, defense, aerospace and biotechnology, according to a company press release.